United Therapeutics Corporation (UTHR) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
United Therapeutics Corporation  (NASDAQ: UTHR)


United Therapeutics's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is United Therapeutics's ROI in the third quarter of 2026?
United Therapeutics Corporation achieved a return on average invested assets (ROI) of 18.61 % in its third quarter of 2026, which is below United Therapeutics's average return on investment, which stands at 19.58%.

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 58 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 350, from total ROI ranking in the second quarter of 2026 at 361.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM -4.95 % -1.57 % 7.1 % 16.91 % 15.08 %
Y / Y Net Income Change TTM -3.22 % 5.54 % 38.04 % 118.66 % 311.42 %
Investment (TTM) in Millions 6,410 6,612 6,115 7,319 6,805
Return On Investment (TTM) 18.61 % 19.53 % 18.64 % 18.71 % 18.28 %
UTHR's Overall Ranking # 350 # 361 # 194 # 324 #
Seq. Investment Change TTM -1.47 % -2.78 % -3.18 % 2.49 % 2.03 %
Seq. Net Income Change TTM -6.11 % 1.83 % -3.54 % 4.95 % 2.38 %
Net Income (TTM) in Millions 1,231 1,311 1,287 1,335 1,272

UTHR Company Profile >> Back to UTHR Roi Comparisons >> See Annual UTHR Return On Investment



Return On Investment UTHR's Ranking
Within: No.
Industry # 27
Sector # 59
Overall # 350

Return On Investment Statistics
High Average Low
57.02 %
19.58 %
-4.83 %
(Jun 30 2016)  







Financial Statements
United Therapeutics's III. Quarter Investments $ 6,410 Millions UTHR's Balance sheet
United Therapeutics's III. Quarter Income $ 259 Millions Quarterly UTHR's Income Statement
UTHR's Income by Division See UTHR's Income by Division


UTHR Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 7,319 6,626 6,363 5,701 4,864
Y / Y Investment Growth 10.47 % 4.14 % 11.6 % 17.22 % 13.33 %
Net Income in Millions 1,335 1,195 985 727 476
Y / Y Net Income Growth 11.68 % 21.35 % 35.4 % 52.86 % -7.58 %
Annual Return On Investment 18.24 % 18.04 % 15.48 % 12.76 % 9.78 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 18.24 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
UTHR's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for UTHR's Competitors
Subscribers only: Roi for United Therapeutics's Suppliers
Subscribers only: Return On Investment for UTHR's Customers

Other Ratios
UTHR's Roa UTHR's Inventory Turnover Ratio UTHR's Growth Rates UTHR's Dividend Statistics
UTHR's Profitability Ratios UTHR's Asset Turnover Ratio UTHR's Dividend Growth
UTHR's Roe UTHR's Valuation Ratios UTHR's Financial Strength Ratios UTHR's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %

Date modified: 2026-11-06T12:55:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.